{
    "nct_id": "NCT04301778",
    "official_title": "A Phase II Study of Durvalumab (MEDI4736) in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma.",
    "inclusion_criteria": "* Have cytologically confirmed intrahepatic cholangiocarcinoma.\n* All disease must be localized to the liver (locally advanced).\n* Subjects must not be deemed surgical candidates.\n* Must be a candidate for conventional transarterial chemoembolization or yttrium-90 radioembolization.\n* Must have measureable disease be mRECIST. Measurable disease will be confirmed by radiological imaging (MRI, CT).\n* Age ≥18 years\n* Body weight > 30 kg\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Life expectancy ≥12 weeks.\n* Patient must have adequate organ function defined by the study-specified laboratory tests as per the protocol.\n* Child Pugh Class A\n* Measured creatinine clearance (CL) >40 mL/min or Calculated creatinine clearance CL>40 mL/min by the Cockcroft-Gault formula.\n* Woman of childbearing potential must have a negative pregnancy test and follow contraceptive guidelines as defined per protocol.\n* Must use acceptable form of birth control while on study.\n* Men must use acceptable form of birth control while on study.\n* Ability to understand and willingness to sign a written informed consent document.\n* Willing and able to comply with the protocol for the duration of the study\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Candidate for surgical resection\n* Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up of an interventional study.\n* Major surgery within 4 weeks prior to initiation of study treatment.\n* Received the last dose of anticancer therapy ≤ 28 days prior to the first dose of study drug.\n* All toxicities NCI CTCAE Grade ≥2 attributed to prior anti-cancer therapy other than alopecia, vitiligo, and neuropathy.\n* Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment.\n* History of allogenic organ transplantation.\n* Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, checkpoint inhibitor-induced immune mediated reaction or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.]).\n* Patient with uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, significant muscle disorders or psychiatric illness/social situations that would limit compliance with study requirements.\n* History of known additional primary malignancies.\n* History of leptomeningeal carcinomatosis.\n* Brain metastases or spinal cord compression.\n* History of active primary immunodeficiency.\n* Infection with Tuberculosis, HIV or hepatitis B or C at screening.\n* Current or prior use of immunosuppressive medication within 14 days before the first dose of treatment.\n* Receipt of live attenuated vaccine within 30 days prior to the first dose of IP.\n* Pregnant or breastfeeding women.\n* Has a history of allergy to study treatments or any of its components of the study.\n* Prior randomization or treatment in a previous durvalumab and/or SNDX-6532 clinical study regardless of treatment arm assignment.\n* Patient has clinically significant heart disease.\n* Any other sound medical, psychiatric, and/or social reason as determined by the Investigator.\n* Unwilling or unable to follow the study schedule for any reason.",
    "miscellaneous_criteria": ""
}